Nebivolol Egis (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Egis, is a beta blocker presented as a tablet for oral use. It treats hypertension and heart failure in adult patients.

GNH USA supplies Nebivolol Egis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular conditions.

Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. Heart failure: improves left‑ventricular function and reduces symptoms in chronic heart failure with reduced ejection fraction. Cardiovascular risk management: contributes to overall risk reduction when combined with lifestyle measures in patients with high blood pressure.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general tiredness. - Nausea or mild gastrointestinal upset. - Bradycardia: heart rate slower than normal. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to fainting. - Acute bronchospasm in patients with reactive airway disease. - Allergic reactions such as rash, pruritus, or angio‑edema. - Hepatic dysfunction manifested by elevated liver enzymes. - Cardiogenic shock in patients with advanced heart failure.

Before initiating Nebivolol, clinicians should consider several safety aspects.

Monitor blood pressure: ensure adequate control and avoid excessive drops. Assess cardiac function: evaluate heart rate and rhythm, especially in patients with pre‑existing bradycardia. Use caution in hepatic impairment: dose adjustments may be required. Avoid abrupt discontinuation: tapering helps prevent rebound hypertension. Contraindicated in severe sinus bradycardia or second‑degree AV block. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with various medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Combined use with other beta‑blockers: may cause excessive bradycardia or hypotension. - Concomitant calcium‑channel blockers verapamil or diltiazem: increase plasma levels and risk of heart block. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): raise Nebivolol concentrations, enhancing adverse effects.

Moderate Interactions (Monitor Closely):\n- Diuretics: may potentiate hypotensive response. - ACE inhibitors or ARBs: additive blood‑pressure lowering effect. - NSAIDs: can blunt antihypertensive response. - Antidiabetic agents: monitor glucose as blood‑pressure changes may affect glycemic control. - Antidepressants other than CYP2D6 inhibitors: watch for additive central nervous system effects.